MXCT Key Statistics, Chart & Performance
The current stock price of MXCT is 1.55 USD. In the past month the price decreased by -1.27%. In the past year, price decreased by -64.69%.
MXCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.87 | 217.71B | ||
| DHR | DANAHER CORP | 29.69 | 161.70B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 183 | 55.61B | ||
| A | AGILENT TECHNOLOGIES INC | 24.39 | 38.58B | ||
| IQV | IQVIA HOLDINGS INC | 19.38 | 38.39B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.32 | 28.48B | ||
| WAT | WATERS CORP | 29.91 | 22.61B | ||
| ILMN | ILLUMINA INC | 30.08 | 20.04B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.92 | 19.79B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.28 | 15.82B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B | ||
| TEM | TEMPUS AI INC | N/A | 10.51B |
Related stock screener links
About MXCT
Company Profile
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Company Info
MAXCYTE INC
9713 Key West Avenue,, Suite 400
Rockville MARYLAND US
CEO: Doug Doerfler
Employees: 114
Phone: 13015175556
MAXCYTE INC / MXCT FAQ
What does MXCT do?
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Can you provide the latest stock price for MAXCYTE INC?
The current stock price of MXCT is 1.55 USD. The price decreased by -0.64% in the last trading session.
Does MAXCYTE INC pay dividends?
MXCT does not pay a dividend.
How is the ChartMill rating for MAXCYTE INC?
MXCT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for MXCT stock?
MAXCYTE INC (MXCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the expected growth for MXCT stock?
The Revenue of MAXCYTE INC (MXCT) is expected to decline by -6.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns MAXCYTE INC?
You can find the ownership structure of MAXCYTE INC (MXCT) on the Ownership tab.
MXCT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MXCT. When comparing the yearly performance of all stocks, MXCT is a bad performer in the overall market: 90.22% of all stocks are doing better.
MXCT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MXCT. While MXCT has a great health rating, there are worries on its profitability.
MXCT Financial Highlights
Over the last trailing twelve months MXCT reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -20.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.38% | ||
| ROE | -25.31% | ||
| Debt/Equity | 0 |
MXCT Forecast & Estimates
13 analysts have analysed MXCT and the average price target is 6.47 USD. This implies a price increase of 317.48% is expected in the next year compared to the current price of 1.55.
For the next year, analysts expect an EPS growth of -4.09% and a revenue growth -6.11% for MXCT